The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.
Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2020 02; 95(2):E34-E35.